Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin

Molecular and Cellular Neuroscience

Volumn 49, Issue 3, 2012, Pages 271-281

  Olson, Scott D ^a   Kambal, Amal ^a   Pollock, Kari ^a   Mitchell, Gaela Marie ^a   Stewart, Heather ^a   Kalomoiris, Stefanos ^a   Cary, Whitney ^a   Nacey, Catherine ^a   Pepper, Karen ^a   Nolta, Jan A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cellular therapy; Huntington's disease; Mesenchymal stem cell; RNAi

Indexed keywords

GREEN FLUORESCENT PROTEIN; HUNTINGTIN; SHORT HAIRPIN RNA;

ARTICLE; CELL HOMING; CELL ORGANELLE; CONTROLLED STUDY; CYTOKINE RELEASE; DENSITOMETRY; DISEASE COURSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IMMUNOMODULATION; MESENCHYMAL STEM CELL; MICROENVIRONMENT; MUTATION; NERVE CELL; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; PROTEIN DEPLETION; REPORTER GENE; RNA INTERFERENCE; RNA TRANSPORT; WESTERN BLOTTING;

CELL LINE; COCULTURE TECHNIQUES; DOWN-REGULATION; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; HUNTINGTON DISEASE; LENTIVIRUS; MESENCHYMAL STEM CELLS; NERVE TISSUE PROTEINS; NEURONS; RNA INTERFERENCE;

MUS MUSCULUS;

EID: 84856808597     PISSN: 10447431     EISSN: 10959327     Source Type: Journal    
DOI: 10.1016/j.mcn.2011.12.001     Document Type: Article

References (42)

1. Bauer G., Dao M.A., Case S.S., Meyerrose T., Wirthlin L., Zhou P., Wang X., Herrbrich P., Arevalo J., Csik S., Skelton D.C., Walker J., Pepper K., Kohn D.B., Nolta J.A. In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors. Mol. Ther. 2008, 16:1308-1315.
2. Biedler J.L., Roffler-Tarlov S., Schachner M., Freedman L.S. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res. 1978, 38:3751-3757.
3. Boudreau R.L., McBride J.L., Martins I., Shen S., Xing Y., Carter B.J., Davidson B.L. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol. Ther. 2009, 17:1053-1063.
4. Boudreau R.L., Rodriguez-Lebron E., Davidson B.L. RNAi medicine for the brain: progresses and challenges. Hum. Mol. Genet. 2011, 20:R21-R27.
5. Bruno S., Grange C., Deregibus M.C., Calogero R.A., Saviozzi S., Collino F., Morando L., Busca A., Falda M., Bussolati B., Tetta C., Camussi G. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J. Am. Soc. Nephrol. 2009, 20:1053-1067.
6. Cornetta K., Anderson W.F. Protamine sulfate as an effective alternative to polybrene in retroviral-mediated gene-transfer: implications for human gene therapy. J. Virol. Methods 1989, 23:187-194.
7. Davidson B.L., Paulson H.L. Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol. 2004, 3(3):145-149.
8. Davidson B.L., McCray P.B. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 2011, 12:329-340.
9. DiFiglia M., Sena-Esteves M., Chase K., Sapp E., Pfister E., Sass M., Yoder J., Reeves P., Pandey R.K., Rajeev K.G., Manoharan M., Sah D.W., Zamore P.D., Aronin N. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17204-17209.
10. Drouet V., Perrin V., Hassig R., Dufour N., Auregan G., Alves S., et al. Sustained effects of nonallele-specific Huntingtin silencing. Ann. Neurol. 2009, 65(3):276-285.
11. Dykxhoorn D.M., Palliser D., Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 2006, 13:541-552.
12. Gahan P.B., Stroun M. The virtosome-a novel cytosolic informative entity and intercellular messenger. Cell Biochem. Funct. 2010, 28:529-538.
13. Gerdes H.H., Carvalho R.N. Intercellular transfer mediated by tunneling nanotubes. Curr. Opin. Cell Biol. 2008, 20:470-475.
14. Harper S.Q., Staber P.D., He X., Eliason S.L., Martins I.H., Mao Q., Yang L., Kotin R.M., Paulson H.L., Davidson B.L. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5820-5825.
15. Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
16. Indraccolo S., Roni V., Zamarchi R., Roccaforte F., Minuzzo S., Stievano L., Habeler W., Marcato N., Tisato V., Tosello V., Chieco-Bianchi L., Amadori A. Expression from cell type-specific enhancer-modified retroviral vectors after transduction: influence of marker gene stability. Gene 2002, 283:199-208.
17. Joyce N., Annett G., Wirthlin L., Olson S., Bauer G., Nolta J.A. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen. Med. 2010, 5:933-946.
18. Kehr J., Buhtz A. Long distance transport and movement of RNA through the phloem. J. Exp. Bot. 2008, 59:85-92.
19. Langbehn D.R., Hayden M.R., Paulsen J.S. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B:397-408.
20. Lombardi M.S., Jaspers L., Spronkmans C., Gellera C., Taroni F., Di Maria E., et al. A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp. Neurol. 2009, 217(2):312-319.
21. Matuskova M., Hlubinova K., Pastorakova A., Hunakova L., Altanerova V., Altaner C., Kucerova L. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett. 2010, 290:58-67.
22. Maxwell M.M. RNAi applications in therapy development for neurodegenerative disease. Curr. Pharm. Des. 2009, 15:3977-3991.
23. Meyerrose T., Rosova I., Dao M., Herrbrich P., Bauer G., Nolta J. Establishment and transduction of primary human stromal/ mesenchymal stem cell monolayers, Vol. Chapter 2 2006, Kluwer Academic Publishers, Dordrecht, the Netherlands.
24. Meyerrose T.E., Roberts M., Ohlemiller K.K., Vogler C.A., Wirthlin L., Nolta J.A., Sands M.S. Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease. Stem Cells 2008, 26:1713-1722.
25. Meyerrose T., Olson S., Pontow S., Kalomoiris S., Jung Y., Annett G., Bauer G., Nolta J.A. Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Adv. Drug Deliv. Rev. 2010, 62:1167-1174.
26. Ogawa R., Mizuno H., Watanabe A., Migita M., Hyakusoku H., Shimada T. Adipogenic differentiation by adipose-derived stem cells harvested from GFP transgenic mice-including relationship of sex differences. Biochem. Biophys. Res. Commun. 2004, 319:511-517.
27. Pfister E.L., Kennington L., Straubhaar J., Wagh S., Liu W., DiFiglia M., et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr. Biol. 2009, 19(9):774-778.
28. Ponten J., Macintyre E.H. Long term culture of normal and neoplastic human glia. Acta Pathol. Microbiol. Scand. 1968, 74:465-486.
29. Quesenberry P.J., Aliotta J.M. The paradoxical dynamism of marrow stem cells: considerations of stem cells, niches, and microvesicles. Stem Cell Rev. 2008, 4:137-147.
30. Ratajczak J., Miekus K., Kucia M., Zhang J., Reca R., Dvorak P., Ratajczak M.Z. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006, 20:847-856.
31. Rodriguez-Lebron E., Gouvion C.M., Moore S.A., Davidson B.L., Paulson H.L. Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease. Mol. Ther. 2009, 17(9):1563-1573.
32. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011, 10:83-98.
33. Sekiya I., Vuoristo J.T., Larson B.L., Prockop D.J. In vitro cartilage formation by human adult stem cells from bone marrow stroma defines the sequence of cellular and molecular events during chondrogenesis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:4397-4402.
34. Shannon K.M. Huntington's disease - clinical signs, symptoms, presymptomatic diagnosis, and diagnosis. Handb. Clin. Neurol. 2011, 100:3-13.
35. Simons M., Raposo G. Exosomes-vesicular carriers for intercellular communication. Curr. Opin. Cell Biol. 2009, 21:575-581.
36. Skinner A.M., O'Neill S.L., Kurre P. Cellular microvesicle pathways can be targeted to transfer genetic information between non-immune cells. PLoS One 2009, 4:e6219.
37. Spees J.L., Olson S.D., Whitney M.J., Prockop D.J. Mitochondrial transfer between cells can rescue aerobic respiration. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1283-1288.
38. Taylor D.D., Gercel-Taylor C. Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin. Immunopathol. 2011, 33(5):441-454.
39. van Bilsen P.H., Jaspers L., Lombardi M.S., Odekerken J.C., Burright E.N., Kaemmerer W.F. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum. Gene Ther. 2008, 19(7):710-719.
40. Waigmann E., Zambryski P. Plasmodesmata. Gateways for rapid information transfer. Curr. Biol. 1994, 4:713-716.
41. Wolvetang E.J., Pera M.F., Zuckerman K.S. Gap junction mediated transport of shRNA between human embryonic stem cells. Biochem. Biophys. Res. Commun. 2007, 363:610-615.
42. Zhang Y., Engelman J., Friedlander R.M. Allele-specific silencing of mutant Huntington's disease gene. J. Neurochem. 2009, 108(1):82-90.